Suppliers / Chemi

Chemi

Italy 257 employees 2 duplicate records merged Updated 9 July 2026

Chemi is an API and finished-dose manufacturer based in Italy. It holds 9 active US drug master files and 6 valid CEPs across a filed portfolio of 10 molecules. Its filings concentrate with AIFA (IT), INFARMED (PT) and FAMHP (BE). Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 26 January 2024 as VAI.

9
active US DMFs
6
valid CEPs
4
registered plants 2 with an FDA FEI number
153
filings across 8 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 26 January 2024 VAI US FDA
  • 9 March 2023 VAI US FDA
  • 20 September 2019 VAI US FDA
  • 25 May 2018 VAI US FDA
  • 12 October 2017 VAI US FDA
  • 12 May 2016 VAI US FDA
  • 3 April 2014 NAI US FDA
  • 28 March 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Cinisello Balsamo, Italy Not on file
Patrica, Italy Not on file
Italy, Italy 3000326763
Italy, Italy 3002806667

What they file, and where

Molecule Regulators Docs
Mesalazine EDQM, SFDA (Saudi Arabia), US FDA 6
Bupropion US FDA 2
Leuprolide EDQM, US FDA 2
Aminoimidazole Carboxamide US FDA 1
Benserazide EDQM 1
Diflunisal US FDA 1
Flunarizine Dihydrochloride EDQM 1
Givinostat US FDA 1
Octreotide US FDA 1
Paroxetine EDQM 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
AIFA (IT) 97 None
INFARMED (PT) 12 None
FAMHP (BE) 10 None
MPA (SE) 9 None
EMA 8 None
US FDA 7 1
MFDS (Korea) None 2

Comparing suppliers?

Choose your molecules and target markets. Chemi comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 5 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 26 January 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates